Literature DB >> 32417409

Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.

Alice Y Ho1, Jean L Wright2, Rachel C Blitzblau3, Robert W Mutter4, Dan G Duda5, Larry Norton6, Aditya Bardia7, Laura Spring7, Steven J Isakoff7, Jonathan H Chen5, Clemens Grassberger5, Jennifer R Bellon8, Sushil Beriwal9, Atif J Khan10, Corey Speers11, Samantha A Dunn5, Alastair Thompson12, Cesar A Santa-Maria13, Ian E Krop14, Elizabeth Mittendorf15, Tari A King15, Gaorav P Gupta16.   

Abstract

Immunotherapy using immune checkpoint blockade has revolutionized the treatment of many types of cancer. Radiation therapy (RT)-particularly when delivered at high doses using newer techniques-may be capable of generating systemic antitumor effects when combined with immunotherapy in breast cancer. These systemic effects might be due to the local immune-priming effects of RT resulting in the expansion and circulation of effector immune cells to distant sites. Although this concept merits further exploration, several challenges need to be overcome. One is an understanding of how the heterogeneity of breast cancers may relate to tumor immunogenicity. Another concerns the need to develop knowledge and expertise in delivery, sequencing, and timing of RT with immunotherapy. Clinical trials addressing these issues are under way. We here review and discuss the particular opportunities and issues regarding this topic, including the design of informative clinical and translational studies. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2020        PMID: 32417409      PMCID: PMC7646202          DOI: 10.1016/j.ijrobp.2020.05.011

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  119 in total

1.  ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Authors:  Frank P Vendetti; Pooja Karukonda; David A Clump; Troy Teo; Ronald Lalonde; Katriana Nugent; Matthew Ballew; Brian F Kiesel; Jan H Beumer; Saumendra N Sarkar; Thomas P Conrads; Mark J O'Connor; Robert L Ferris; Phuoc T Tran; Greg M Delgoffe; Christopher J Bakkenist
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

2.  The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients.

Authors:  Marie-Catherine Vozenin; Pauline De Fornel; Kristoffer Petersson; Patrick Devauchelle; Jean Bourhis; Vincent Favaudon; Maud Jaccard; Jean-François Germond; Benoit Petit; Marco Burki; Gisèle Ferrand; David Patin; Hanan Bouchaab; Mahmut Ozsahin; François Bochud; Claude Bailat
Journal:  Clin Cancer Res       Date:  2018-06-06       Impact factor: 12.531

3.  Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes.

Authors:  Christof C Smith; Shengjie Chai; Amber R Washington; Samuel J Lee; Elisa Landoni; Kevin Field; Jason Garness; Lisa M Bixby; Sara R Selitsky; Joel S Parker; Barbara Savoldo; Jonathan S Serody; Benjamin G Vincent
Journal:  Cancer Immunol Res       Date:  2019-09-12       Impact factor: 11.151

4.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Authors:  Robert M Samstein; Chung-Han Lee; Alexander N Shoushtari; Matthew D Hellmann; Ronglai Shen; Yelena Y Janjigian; David A Barron; Ahmet Zehir; Emmet J Jordan; Antonio Omuro; Thomas J Kaley; Sviatoslav M Kendall; Robert J Motzer; A Ari Hakimi; Martin H Voss; Paul Russo; Jonathan Rosenberg; Gopa Iyer; Bernard H Bochner; Dean F Bajorin; Hikmat A Al-Ahmadie; Jamie E Chaft; Charles M Rudin; Gregory J Riely; Shrujal Baxi; Alan L Ho; Richard J Wong; David G Pfister; Jedd D Wolchok; Christopher A Barker; Philip H Gutin; Cameron W Brennan; Viviane Tabar; Ingo K Mellinghoff; Lisa M DeAngelis; Charlotte E Ariyan; Nancy Lee; William D Tap; Mrinal M Gounder; Sandra P D'Angelo; Leonard Saltz; Zsofia K Stadler; Howard I Scher; Jose Baselga; Pedram Razavi; Christopher A Klebanoff; Rona Yaeger; Neil H Segal; Geoffrey Y Ku; Ronald P DeMatteo; Marc Ladanyi; Naiyer A Rizvi; Michael F Berger; Nadeem Riaz; David B Solit; Timothy A Chan; Luc G T Morris
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

5.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

Review 6.  Assessing the interactions between radiotherapy and antitumour immunity.

Authors:  Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2019-06-26       Impact factor: 66.675

7.  Predicting HLA class II antigen presentation through integrated deep learning.

Authors:  Binbin Chen; Michael S Khodadoust; Niclas Olsson; Lisa E Wagar; Ethan Fast; Chih Long Liu; Yagmur Muftuoglu; Brian J Sworder; Maximilian Diehn; Ronald Levy; Mark M Davis; Joshua E Elias; Russ B Altman; Ash A Alizadeh
Journal:  Nat Biotechnol       Date:  2019-10-14       Impact factor: 54.908

8.  Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.

Authors:  Aleix Prat; Cheng Fan; Aranzazu Fernández; Katherine A Hoadley; Rossella Martinello; Maria Vidal; Margarita Viladot; Estela Pineda; Ana Arance; Montserrat Muñoz; Laia Paré; Maggie C U Cheang; Barbara Adamo; Charles M Perou
Journal:  BMC Med       Date:  2015-12-18       Impact factor: 8.775

9.  Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.

Authors:  Martin Sjöström; S Laura Chang; Nick Fishbane; Elai Davicioni; Shuang G Zhao; Linda Hartman; Erik Holmberg; Felix Y Feng; Corey W Speers; Lori J Pierce; Per Malmström; Mårten Fernö; Per Karlsson
Journal:  J Clin Oncol       Date:  2019-10-16       Impact factor: 44.544

10.  3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen.

Authors:  Robert W Mutter; Krishan R Jethwa; Karthik Gonuguntla; Nicholas B Remmes; Thomas J Whitaker; Tina J Hieken; Kathryn J Ruddy; Lisa A McGee; Kimberly S Corbin; Sean S Park
Journal:  Radiat Oncol       Date:  2019-11-21       Impact factor: 3.481

View more
  6 in total

1.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

2.  RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.

Authors:  Andrea M Pesch; Nicole H Hirsh; Anna R Michmerhuizen; Kassidy M Jungles; Kari Wilder-Romans; Benjamin C Chandler; Meilan Liu; Lynn M Lerner; Charles A Nino; Connor Ward; Erin F Cobain; Theodore S Lawrence; Lori J Pierce; James M Rae; Corey W Speers
Journal:  JCI Insight       Date:  2022-02-08

3.  Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future".

Authors:  Nhu Hanh To; Nina Radosevic-Robin; Yazid Belkacemi
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

Review 4.  Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.

Authors:  Nusayba A Bagegni; Andrew A Davis; Katherine K Clifton; Foluso O Ademuyiwa
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-04-29

Review 5.  Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.

Authors:  Marc D Piroth; David Krug; Petra Feyer; René Baumann; Stephanie Combs; Marciana-Nona Duma; Jürgen Dunst; Gerd Fastner; Rainer Fietkau; Matthias Guckenberger; Wulf Haase; Wolfgang Harms; Thomas Hehr; Felix Sedlmayer; Rainer Souchon; V Strnad; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2022-05-08       Impact factor: 4.033

6.  Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.

Authors:  Yun Hu; Sébastien Paris; Genevieve Bertolet; Hampartsoum B Barsoumian; Kewen He; Duygu Sezen; Dawei Chen; Mark Wasley; Jordan DA Silva; Joylise A Mitchell; Tiffany A Voss; Fatemeh Masrorpour; Claudia Kettlun Leyton; Liangpeng Yang; Carola Leuschner; Nahum Puebla-Osorio; Saumil Gandhi; Quynh-Nhu Nguyen; Maria Angelica Cortez; James W Welsh
Journal:  J Nanobiotechnology       Date:  2022-09-19       Impact factor: 9.429

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.